bioRxivNeurosciencePreprint
Gene identification for ocular congenital cranial motor neuron disorders using human sequencing, zebrafish screening, and protein binding microarrays
Julie A. JurgensiD, Paola M. Matos Ruiz, Jessica King, Emma E. Foster, Lindsay Berube, Wai Man ChaniD, Brenda J. BarryiD, Raehoon JeongiD, Elisabeth Rothman, Mary C. WhitmaniD, Sarah E. MacKinnon, Cristina Rivera QuilesiD, Brandon M. PrattiD, Teresa EasterbrooksiD, Fiona M. Mensching, Silvio Alessandro Di GioiaiD, Lynn S. PaisiD, Eleina M. England, Teresa de BerardinisiD, Adriano MagliiD, Feray KoçiD, Kazuhide AsakawaiD, Koichi KawakamiiD, Anne O’Donnell‐LuriaiD, David G. HunteriD, , Elizabeth C. EngleiD
Abstract
PurposeTo functionally evaluate novel human sequence-derived candidate genes and variants for unsolved ocular congenital cranial dysinnervation disorders (oCCDDs). MethodsThrough exome and genome sequencing of a genetically unsolved human oCCDD cohort, we previously identified variants in 80 strong candidate genes. Here, we further prioritized a subset of these (43 human genes, 57 zebrafish genes) using a G0 CRISPR/Cas9-based knockout assay in zebrafish and generated F2 germline mutants for seventeen. We tested the functionality of variants of uncertain significance in known and novel candidate transcription factor-encoding genes through protein binding microarrays. ResultsWe first demonstrated the feasibility of the G0 screen by targeting known oCCDD genes phox2a and mafba. 70-90% of gene-targeted G0 zebrafish embryos recapitulated germline homozygous null-equivalent phenotypes. Using this approach, we then identified three novel candidate oCCDD genes (SEMA3F, OLIG2, and FRMD4B) with putative contributions to human and zebrafish cranial motor development. In addition, protein binding microarrays demonstrated reduced or abolished DNA binding of human variants of uncertain significance in known and novel sequence-derived transcription factors PHOX2A (p.(Trp137Cys)), MAFB (p.(Glu223Lys)), and OLIG2 (p.(Arg156Leu)). ConclusionsThis study nominates three strong novel candidate oCCDD genes (SEMA3F, OLIG2, and FRMD4B) and supports the functionality and putative pathogenicity of transcription factor candidate variants PHOX2A p.(Trp137Cys), MAFB p.(Glu223Lys), and OLIG2 p.(Arg156Leu). Our findings support that G0 loss-of-function screening in zebrafish can be coupled with human sequence analysis and protein binding microarrays to aid in prioritizing oCCDD candidate genes/variants.
- organism: zebrafish
- organism: human
- assay: whole-exome sequencing
- assay: whole-genome sequencing
- research focus: gene regulatory network inference
- research focus: variant effect prediction
- approach: experimental assay
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Characterizing CSNK2A1 Mutant-Induced Morphological Phenotypes in Zebrafish (Danio rerio): Insights into Okur-Chung Neurodevelopmental Syndrome (OCNDS)
Katie Hassett, Sai Srihaas Potu, … Sampathkumar Rangasamy·bioRxiv·Jan 9, 2024
- Transcriptional profiling of extraocular motor neurons reveals sim1a as a candidate strabismus-related gene
Emily Gershowitz, Kyla Rose Hamling, … David Schoppik·bioRxiv·Apr 8, 2026
- Novel pre-clinical model for CDKL5 Deficiency Disorder
Rita J. Serrano, Clara Lee, … Tamar E. Sztal·Disease Models & MechanismsPeer-reviewed·Dec 16, 2021
- Examining craniofacial variation among crispant and mutant zebrafish models of human skeletal diseases
Kelly M. Diamond, Abigail E. Burtner, … A. Murat Maga·Journal of AnatomyPeer-reviewed·Mar 1, 2023
- Crispant analysis in zebrafish as a tool for rapid functional screening of disease-causing genes for bone fragility
Sophie Debaenst, Tamara Jarayseh, … Andy Willaert·eLifePeer-reviewed·Jan 16, 2025
- Identification of novel coloboma candidate genes through conserved gene expression analyses across four vertebrate species
Violeta Trejo-Reveles, Nicholas Owen, … Joe Rainger·BiomoleculesPeer-reviewed·Feb 4, 2023